Article of the day, September 2nd, suggested by the Immune Oncology Research Institute

Immune Oncology Research Institute shared a post on LinkedIn:

“Article of the day! Suggest by the Immune Oncology Research Institute.

Perioperative Nivolumab in Resectable Lung Cancer

Authors: Tina Cascone, Mark M. Awad, Jonathan D. Spicer, Jie He, Shun Lu, Boris Sepesi, Fumihiro Tanaka, Janis M. Taube, Robin Cornelissen, Libor Havel, Nina Karaseva, Jaroslaw Kuzdzal, Lubos B. Petruzelka, Lin Wu, Jean-Louis Pujol, Hiroyuki Ito, Tudor-Eliade Ciuleanu, Ludmila de Oliveira Muniz Koch, Annelies Janssens, Aurelia Alexandru, Sabine Bohnet, Fedor V. Moiseyenko, Yang Gao, Yasutaka Watanabe, Cinthya Coronado Erdmann, Padma Sathyanarayana, Stephanie Meadows-Shropshire, Steven I. Blum and Mariano Provencio Pulla.

Author Affiliations: MD Anderson Cancer Center, Dana-Farber Cancer Institute, McGill University Health Center, Peking Union Medical College, Shanghai Jiao Tong University, University of Occupational and Environmental Health Japan, Erasmus MC ,CHU de Montpellier ,BRYSTOL MYERS SQUIBB SL, et al.

Source: Immune Oncology Research Institute/LinkedIn

Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.

Other posts featuring Immune Oncology Research Institute on OncoDaily.